Literature DB >> 10746543

The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors.

J C Yang1, D Perry-Lalley.   

Abstract

Recently, significant progress has been made in identifying specific tumor-associated antigens recognized by T cells and defining the specific peptide epitopes within these proteins that are processed and presented on class I major histocompatibility antigens. Most of these antigens have been identified in human melanoma, where many of them appear to be tissue-specific, nonmutated proteins expressed by melanoma and normal melanocytes but not by other tissues. There has been much less progress in identifying the tumor antigens on murine tumors that are recognized by T cells, and this has restricted the development of preclinical animal models for immunotherapy. The authors previously described a method for generating tumor-reactive T cells from murine tumors (tumor infiltrating lymphocytes) that are CD8+ T cells recognizing autologous tumor and that can inhibit established tumor on adoptive transfer. Here the authors show that the envelope protein of an endogenous murine retrovirus of the AKV family, found in the germline of the C57BL/6 mouse, is recognized by tumor-infiltrating lymphocytes from two histologically different tumors syngeneic to that mouse strain. Furthermore, the authors identify the specific 9-amino acid peptide from the p15E transmembrane component of this envelope protein that is recognized in the context of major histocompatibility complex Kb, show that it is naturally presented and recognized on several other H-2b tumors, and that cytotoxic T lymphocytes specific for this epitope are therapeutic for these antigen-expressing tumors on adoptive transfer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10746543     DOI: 10.1097/00002371-200003000-00001

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  23 in total

1.  Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation.

Authors:  James W Hodge; Hadley J Sharp; Sofia R Gameiro
Journal:  Cancer Biother Radiopharm       Date:  2012-01-27       Impact factor: 3.099

2.  4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.

Authors:  Chie Kudo-Saito; James W Hodge; Heesun Kwak; Seunghee Kim-Schulze; Jeffrey Schlom; Howard L Kaufman
Journal:  Vaccine       Date:  2006-03-31       Impact factor: 3.641

3.  Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.

Authors:  Toshihiro Nagato; Young-Ran Lee; Yasuaki Harabuchi; Esteban Celis
Journal:  Clin Cancer Res       Date:  2014-01-03       Impact factor: 12.531

4.  Immunization against endogenous retroviral tumor-associated antigens.

Authors:  M H Kershaw; C Hsu; W Mondesire; L L Parker; G Wang; W W Overwijk; R Lapointe; J C Yang; R F Wang; N P Restifo; P Hwu
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

5.  Intratumoral immunotherapy of established solid tumors with chitosan/IL-12.

Authors:  David A Zaharoff; Kenneth W Hance; Connie J Rogers; Jeffrey Schlom; John W Greiner
Journal:  J Immunother       Date:  2010-09       Impact factor: 4.456

Review 6.  Retroelements and the human genome: new perspectives on an old relation.

Authors:  Norbert Bannert; Reinhard Kurth
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

7.  CTL activation using the natural low-affinity epitope 222-229 from tyrosinase-related protein 1 leads to tumor rejection.

Authors:  Kevin D Pavelko; Michael J Hansen; Larry R Pease
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

8.  Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.

Authors:  C Bauer; F Bauernfeind; A Sterzik; M Orban; M Schnurr; H A Lehr; S Endres; A Eigler; M Dauer
Journal:  Gut       Date:  2007-03-29       Impact factor: 23.059

9.  Age-dependent tolerance to an endogenous tumor-associated antigen.

Authors:  Jennifer A McWilliams; Richard T Sullivan; Kimberly R Jordan; Rachel H McMahan; Charles B Kemmler; Marcia McDuffie; Jill E Slansky
Journal:  Vaccine       Date:  2008-02-20       Impact factor: 3.641

10.  The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects.

Authors:  Cláudia C Oliveira; Peter A van Veelen; Bianca Querido; Arnoud de Ru; Marjolein Sluijter; Sandra Laban; Jan W Drijfhout; Sjoerd H van der Burg; Rienk Offringa; Thorbald van Hall
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.